← Back to patent-cliff list
Ifupinostat Hydrochloride
Tier C — Watch / tradeIfupinostat Hydrochloride
-
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Class I PI3K, HDAC
Indications (approved)：Diffuse large B-cell lymphoma
Regional status
US
-
EU
-
China
Approved
2025-06-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ifupinostat Hydrochloride?
Approved indications include: Diffuse large B-cell lymphoma.
When does the Ifupinostat Hydrochloride patent expire?
No public expiry year is available for Ifupinostat Hydrochloride yet; this page updates once verified.
How do I get a quote for Ifupinostat Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01